InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,010.60
(
0.00%
)
US TECH 100
16,819.60
(
0.40%
)
Dow Jones
38,239.98
(
0.00%
)
Brent Oil
85.76
(
-0.76%
)
Bitcoin
66,121.46
(
-1.10%
)
MIRN
Mirna Therapeutics
NASDAQ
Add Alert
Follow
5
MIRN
Mirna Therapeutics
NASDAQ
Add Alert
Follow
5

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up
Live Updating
Older
Newer
profile icon
wiltonio Free
05/23/17 4:09 PM
Post #83
Last Read
profile icon
$Pistol Pete$ Free
01/02/17 7:26 PM
Post #82
Last Read
profile icon
DIIV - Oshin Free
11/23/16 3:46 AM
Post #81
Re: #80: @$Pistol Pete$ - Strong close
Last Read
profile icon
$Pistol Pete$ Free
11/23/16 12:50 AM
Post #80
Last Read
profile icon
ClayTrader Free
11/21/16 5:29 PM
Post #79
Last Read
profile icon
$Pistol Pete$ Free
10/19/16 9:03 PM
Post #78
Last Read
profile icon
RISK-TAKER Free
09/21/16 9:30 AM
Post #77
Re: #76: @Murph32 - It's official, you were indeed missing something.
Last Read
profile icon
Murph32 Free
09/20/16 4:52 PM
Post #76
Re: #74: @RISK-TAKER - $72 million cash..no debt..20 million share out..
Last Read
profile icon
RISK-TAKER Free
08/30/16 11:38 PM
Post #74
Re: #73: @RISK-TAKER - Big drop...found no news..took a RISK @ $2.49 ..
Last Read
profile icon
RISK-TAKER Free
08/30/16 5:55 PM
Post #73
Last Read
profile icon
$Pistol Pete$ Free
08/21/16 8:36 PM
Post #72
Last Read
profile icon
$Pistol Pete$ Free
07/04/16 8:31 AM
Post #70
Last Read
profile icon
$Pistol Pete$ Free
06/13/16 11:51 PM
Post #69
Last Read
profile icon
$Pistol Pete$ Free
05/08/16 7:51 PM
Post #68
Last Read
profile icon
Peacefulwendy Free
04/13/16 12:48 PM
Post #66
Re: #64: @$Pistol Pete$ - Yes Wendy
Last Read
profile icon
$Pistol Pete$ Free
04/13/16 12:24 PM
Post #65
Re: #63: @Peacefulwendy - Is the chart looking good?
Last Read
profile icon
$Pistol Pete$ Free
04/13/16 1:23 AM
Post #62
Re: #61: @Peacefulwendy - Annual Report...
Last Read
profile icon
$Pistol Pete$ Free
03/22/16 9:13 PM
Post #60
Re: #59: @Peacefulwendy - I plan to attend...
Last Read
profile icon
Peacefulwendy Free
03/22/16 9:10 PM
Post #59
Re: #58: @$Pistol Pete$ - $MIRN Daily and Weekly Charts http://www.stock
Last Read
profile icon
$Pistol Pete$ Free
03/19/16 11:03 PM
Post #58
Last Read
profile icon
$Pistol Pete$ Free
02/20/16 2:58 PM
Post #57
Re: #56: @Peacefulwendy - With a lot of upside potential. Did you
Last Read
profile icon
Peacefulwendy Free
02/20/16 2:53 PM
Post #56
Re: #55: @$Pistol Pete$ - Yes and I think it is another long
Last Read
profile icon
$Pistol Pete$ Free
02/20/16 2:51 PM
Post #55
Re: #54: @Peacefulwendy - You holding? I am a little bit...
Last Read
profile icon
Peacefulwendy Free
02/20/16 2:47 PM
Post #54
Re: #52: @$Pistol Pete$ - $MIRN Daily and Weekly Charts http://www.stock
Last Read
profile icon
$Pistol Pete$ Free
02/19/16 10:12 PM
Post #53
Last Read
profile icon
$Pistol Pete$ Free
02/18/16 9:33 PM
Post #52
Last Read
profile icon
$Pistol Pete$ Free
02/14/16 5:06 PM
Post #51
Last Read
profile icon
$Pistol Pete$ Free
01/25/16 10:35 PM
Post #50
Last Read
profile icon
$Pistol Pete$ Free
01/16/16 6:22 PM
Post #48
Last Read
profile icon
yorky Free
01/11/16 8:16 AM
Post #47
Last Read
profile icon
$Pistol Pete$ Free
01/10/16 10:59 PM
Post #46
Last Read
profile icon
$Pistol Pete$ Free
12/27/15 4:40 PM
Post #45
Last Read
profile icon
$Pistol Pete$ Free
12/08/15 7:06 PM
Post #44
Last Read
profile icon
$Pistol Pete$ Free
11/27/15 9:15 PM
Post #43
Last Read
profile icon
mick Grandfathered
11/16/15 8:05 PM
Post #42
Last Read
profile icon
$Pistol Pete$ Free
11/09/15 7:05 PM
Post #41
Re: #40: @Peacefulwendy - Mirna Therapeutics Announces Presentation of Interim Data from
Last Read
profile icon
Peacefulwendy Free
11/09/15 10:12 AM
Post #40
Last Read
profile icon
mick Grandfathered
10/27/15 3:05 PM
Post #38
Re: #37: @Peacefulwendy - Thanks mick.
Last Read
profile icon
Peacefulwendy Free
10/27/15 11:11 AM
Post #35
Last Read
Older
Newer

Mirna Therapeutics (MIRN) RSS Feed

Followers
5
Posters
10
Posts (Today)
0
Posts (Total)
84
Created
10/20/15
Type
Free
Moderators



Welcome to Mirna Therapeutics (MIRN) Boardsmiley

 

About Mirna Therapeutics

Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer.
 
Mirna’s lead product candidate, MRX34, is the first microRNA mimic to enter clinical development and has demonstrated clinical proof of concept as a single agent in our ongoing Phase 1 clinical trial. MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is under expressed in a wide variety of cancers. MRX34 entered clinical testing in 2013 and is being studied in a multicenter, open-label Phase 1 trial in patients with primary liver cancer, other solid cancers, and hematological malignancies (lymphomas and leukemias). Dose escalation in the Phase 1 clinical trial is expected to be completed by the end of 2015, and we plan to complete enrollment of several expansion cohorts and have multiple study data read-outs in different tumor types by the end of 2016.

We believe microRNA Replacement Therapy restores the body’s natural ability to fight cancer on multiple levels, including repression of tumor immune evasion, tumor growth, cancer stem cells and metastasis, by replacing naturally occurring tumor suppressor microRNAs that are under expressed in cancer cells with microRNA mimics. We believe controlling these multiple cancer pathways may also reduce the risk of the development of drug resistance, one of the more prevalent problems of modern cancer therapies.

Our pipeline is based on microRNAs. We believe tumor suppressor microRNA mimics have potential as cancer therapeutics due to their capacity to regulate many different oncogenes across multiple pathways, as compared to other targeted cancer therapies that affect only one or two oncogenes or oncogenic pathways. Some of these miRNA mimics may also repress checkpoint signaling molecules to inhibit tumor evasion pathways. We have identified multiple tumor suppressor microRNAs that have demonstrated the ability to inhibit cancer cell proliferation and tumor growth in preclinical studies. Each tumor suppressor miRNA regulates a unique set of genes and oncogenic pathways that we believe will enable the development of multiple therapeutic candidates either as monotherapies or as combination therapies. We plan to initiate a Phase 1 trial for our second therapeutic candidate in 2016.

Mirna’s owned and in-licensed intellectual property portfolio includes at least 10 issued U.S. patents and more than 42 pending U.S. and foreign applications.

Mirna Therapeutics was founded in 2007 and is located in Austin, Texas.

Mirna’s microRNA Replacement Therapy Technology

Mirna is developing a potential first-in-class cancer therapy, known as microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics. 

Preclinical studies have shown that mimics of naturally occurring microRNAs can reduce the proliferation of cultured cancer cells, cause significant tumor regression in mouse models and reduce the tumor-forming capacity of cancer stem cells. We believe controlling these multiple cancer pathways may also reduce the risk of the development of drug resistance, one of the more prevalent problems of modern cancer therapies.



Many of today’s cancer treatments were designed to target only one or two oncogenes or pathways. In contrast, microRNA Replacement Therapy is designed to inhibit multiple oncogenic pathways. Because of this unique attribute, we believe that microRNA Replacement Therapy may be a more effective approach to treat complex, multi-factorial diseases, such as cancer.

Mirna has identified several tumor suppressor microRNAs that we believe play key roles in preventing normal cells from becoming cancerous; these microRNAs are reduced or lost in virtually all cancers and to varying degrees also in cancer stem cells.

Mirna’s approach to creating microRNA replacement therapeutics builds on the following proprietary technologies and capabilities: 
  • microRNA Pipeline: The selection of microRNA targets for therapeutic development is guided by more than a decade of experience of our scientists in the research and discovery of the expression, function and therapeutic application of microRNAs. We consider ideal therapeutic candidates to be those that have strong evidence for application in human disease and are most effective in preclinical in vitro andin vivo animal studies.
    Chemistry: Mirna has developed a series of proprietary double-stranded microRNA molecules that include a mimic of the natural microRNA sequence. The active strand of the mimic contains a sequence identical to the microRNA that is normally expressed in the target cell. The second, passenger strand is modified to facilitate proper loading of the active strand into the protein complex necessary for microRNA function.
    Drug Delivery: Due to recent advances in delivery technologies for RNA-based therapeutics, Mirna established proprietary model systems and analytical methods to assess and develop these drug delivery technologies. Mirna continues to evaluate delivery technologies to target a broader group of tissues and tumor types.
As a result of these efforts, Mirna has secured an exclusive license from Marina Biotech, Inc. to the patent estate covering the SMARTICLES® liposomal delivery technology for several of our lead microRNA product candidates, including miR-34, let-7 and three other targets. The SMARTICLES formulation offers key efficacy and safety benefits, including the ability to deliver high numbers of microRNA mimic molecules to both healthy and cancerous cells, including tumor cells located in the liver, lymph nodes (melanoma metastasis), lung and colon, as well as to highly vascularized tissues, such as adrenal gland and kidney, and also to bone marrow. Mirna continues to evaluate alternative delivery technologies to target additional tissues and tumor types.

Mirna continues to welcome collaborative inquiries related to the in vivo delivery of oligonucleotides. Please contact busdev@mirnarx.com. 
 
Therapeutic Advantages

microRNA tumor suppressor mimics represent a potential first-in-class cancer therapy:
  • microRNAs can function as natural tumor suppressors, acting as endogenous regulators of cancer, including tumor growth, cancer stem cells and metastasis
    microRNAs control multiple pathways, presenting the prospect of one microRNA mimic regulating numerous oncogenes across multiple cancer pathways, as well as tumor immune evasion pathways
    microRNAs are abundantly present in most normal human cells



    •  
Tumor suppressor microRNAs inhibit the expression of multiple oncogenes, whether they function within the same or across multiple pathways. As a result, tumor suppressor microRNAs can inhibit a variety of cancer processes and have the potential to inhibit a broad range of cancer types. For example, miR-34, the naturally occurring microRNA that is the basis of Mirna’s MRX34, has been shown to regulate more than 30 oncogenes, including many that are the target of FDA-approved and investigational cancer drugs, as well as the immune-oncology checkpoint molecule PD-L1.

Management

Mirna has assembled an experienced management team with leaders in microRNA and cancer research, and all aspects of drug and business development.
 

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Paul Lammers, M.D., M.Sc.
President & Chief Executive Officer

Mirna-Michael Powell
Dr. Paul Lammers has served as a member of Mirna’s board of directors and as President and Chief Executive Officer since November 2009. Previously, Dr. Lammers was the President of Repros Therapeutics Inc., a biopharmaceutical company. Dr. Lammers has also served as the Chief Medical Officer for EMD Serono, Inc., a biopharmaceutical division of Merck KGaA, Senior Vice President of clinical and regulatory affairs at Zonagen, Inc., which later became Repros Therapeutics, and Organon International, a pharmaceutical company, spending eight years in the commercial and clinical operations in Europe and the United States. Dr. Lammers received an M.Sc. and M.D. from the Catholic University (Radboud University) in Nijmegen, The Netherlands.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Miguel Barbosa, Ph.D.
Chief Scientific Officer

Mirna-Michael Powell
Dr. Barbosa has served as our Chief Scientific Officer since September 2015. Prior to joining Mirna, Dr. Barbosa served as an Executive in Residence, Therapeutic Innovation, at Johnson & Johnson Innovation, a pharmaceutical company and part of The Johnson & Johnson Family of Companies, or J&J, where he led the identification and development of new research and development and business models. Previously, Dr. Barbosa served as Vice President, Immunology Research & External Innovation and as Vice President, Immunology Research at Janssen Research & Development L.L.C., a J&J company. Additionally, Dr. Barbosa served in various roles, including Vice President, Discovery Research, at Centocor Research & Development, Inc., also a J&J company. Dr. Barbosa received a B.S. in Genetics from the University of California, Davis, and a Ph.D. in Microbiology & Immunology from the University of California, Los Angeles.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Sinil Kim, M.D.
Vice President Oncology & Chief Medical Officer

Mirna-Michael Powell
Dr. Sinil Kim has served as the Chief Medical Officer and Vice President of Oncology at Mirna Therapeutics since May 2013. Previously, Dr. Kim served as Senior Director and Global Clinical Leader at Pfizer, Inc. and as a Director of Clinical Oncology with Bristol-Myers Squibb. He also co-founded DepoTech Corp, a pharmaceutical company. Dr. Kim received his bachelor’s degree in chemistry and M.D. from the University of Washington and completed his postdoctoral fellowship in hematology and oncology at the University of California San Diego.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Casi DeYoung, M.B.A.
Chief Business Officer

Mirna-Michael Powell
Ms. Casi DeYoung joined Mirna Therapeutics in March 2014 as Chief Business Officer. Prior to Mirna, Ms. DeYoung served as Vice President of Business Development at Reata Pharmaceuticals. Previously, Ms. DeYoung served as the Vice President of Business Development for ODC Therapy, Inc., an immunotherapy company. Ms. DeYoung has also served in various commercial and business development roles, including Director of Global Oncology Operations for EMD Pharmaceuticals, Inc., the U.S. affiliate of Merck KGaA. Ms. DeYoung received a bachelor’s degree in chemistry from Southwestern University and an M.B.A. from the University of Texas at Austin.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Alan Fuhrman
Chief Financial Officer

Alan Fuhrman has served as our Chief Financial Officer since September 2015. Mr. Fuhrman previously served as the Chief Financial Officer of Ambit Biosciences Corporation, a biopharmaceutical company, including through the company’s initial public offering in 2013 and until its sale to Daiichi Sankyo for up to $410 million. Prior to this role, Mr. Fuhrman served as Chief Financial Officer of Naviscan, Inc., a privately held medical imaging company and as Chief Financial Officer of Sonus Pharmaceuticals, Inc., a pharmaceutical company. Mr. Fuhrman is a member of the board of directors of Loxo Oncology, Inc. Earlier in Mr. Fuhrman’s career he practiced as a CPA with Coopers and Lybrand. Mr. Fuhrman received a B.S. in both Business Administration and Agricultural Economics from Montana State University.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Andreas Bader, Ph.D., M.S.
Vice President Translational Research & Development

Mirna-Michael Powell
Dr. Andreas Bader joined Mirna Therapeutics in December 2007 and has served as Director of Analytical and External Research since January 2012. Previously, he served as the Project Lead of the microRNA therapeutics program at Asuragen. Prior to joining Asuragen, Dr. Bader held a faculty position at The Scripps Research Institute, La Jolla, California, where he also completed his postdoctoral training, focusing on molecular mechanisms of cancer and the identification of novel cancer drug targets. Dr. Bader received his M.S. in biology and his Ph.D. in biochemistry from the University of Innsbruck, Austria.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">David Brown, Ph.D.
Vice President Preclinical Pharmacology

Mirna-Michael Powell
Dr. David Brown has served as Director of Drug Discovery and in vivoResearch at Mirna Therapeutics since January 2012 after joining Mirna Therapeutics in December 2007. Previously, Dr. Brown was the Director of Discovery at Asuragen, Inc., where he oversaw efforts to identify diagnostic and therapeutic applications for microRNAs. Dr. Brown also served in the R&D Department at Ambion, Inc. and developed research products for the life sciences market. Dr. Brown received his Ph.D. in molecular biology from the University of Colorado and currently serves as an Adjunct Professor at the University of Texas MD Anderson Cancer Center.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Jon Irvin
Vice President Finance

Mirna-Michael Powell
Mr. Jon Irvin has served at our company since November 2012, first as a Chief Financial Officer Consultant with Bridgepoint Consulting, LLC, or Bridgepoint, a consulting firm providing financial consulting assistance to various organizations, and then as our employee beginning in April 2013. Mr. Irvin currently serves as our Vice President of Finance. Prior to joining Mirna, Mr. Irvin was an independent consultant in Austin, Texas. He also served as the Chief Executive Officer and Vice President of Finance for Voxpath Networks, Inc., a telecommunications and intellectual property company. Previously, Mr. Irvin held various finance positions at Reddwerks Corporation, a software company, Esoterix, Inc., a medical labs company, Topaz Technologies, a pharmaceutical software company, and BioNumerik Pharmaceuticals, Inc., a pharmaceutical company. Mr. Irvin was previously an accountant with Price Waterhouse and Ernst & Young. He received a B.S. in Accounting from the University of Illinois.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Neil Leatherbury, M.S.
Director, Pharmaceutical Development

Mirna-Michael Powell
Mr. Leatherbury joined Mirna Therapeutics as the Director of Pharmaceutical Development in 2010. Prior to Mirna, he was Director of Product Development at Azaya Therapeutics, developing liposomal delivery systems for water insoluble drugs. He also worked as a Senior Engineer at OsteoBiologics, developing bio-absorbable tissue engineering implants primarily for orthopedic indications. His main focus is on product development of early-stage therapies and their rapid translation from lab bench to the clinic. Mr. Leatherbury received his bachelor’s degree in chemical engineering from Rice University and a M.S. in management of technology from the University of Texas at San Antonio.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Jay Stoudemire, Ph.D.
Vice President Preclinical Development, Regulatory & Quality Assurance

Mirna-Michael Powell
Dr. Stoudemire is the Vice President, Preclinical Development, Regulatory & Quality Assurance at Mirna Therapeutics. Prior to oining Mirna in 2010, he has held positions at Genentech, Ascenta Therapeutics, Chugai-Roche Pharmaceuticals, Cytel, Genetics Institute, and Xoma, with responsibility for the pharmacokinetic and toxicological evaluations of a range of small molecules and biologics, including cytokines, growth and hematopoietic factors, monoclonal antibodies and pro-apoptotic therapeutics. Dr. Stoudemire received his Ph.D. in microbiology from the University of Miami and completed a postdoctoral fellowship in the Cardiovascular Research Institute at the University of California San Francisco.

Board of Directors
 

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Michael Powell, Ph.D.
Managing General Partner, Sofinnova Ventures (Chairman)

Mirna-Michael Powell
Dr. Michael Powell has served as Chairman of the board of directors at Mirna Therapeutics since October 2012. Dr. Powell has been a General Partner of Sofinnova Ventures, a venture capital firm, since 1997. Previously, Dr. Powell has held positions at Genentech, a biotechnology company, Cytel, a research and development company, and Syntex Research Group, a pharmaceutical company. Dr. Powell is currently a director of several private biopharmaceutical companies, and Ocera Therapeutics, a publicly traded biopharmaceutical company. Dr. Powell is an Adjunct Professor at the University of Kansas. He is also the Board President of the AIDS Vaccine Advocacy Coalition and serves on the advisory board of the Institute for the Advancement of Medical Innovation at the University of Kansas. Dr. Powell received a Ph.D. in physical chemistry from the University of Toronto, and completed his postdoctoral work in bioorganic chemistry at the University of California.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Larry Alleva

Mirna-Michael Powell
Lawrence (Larry) M. Alleva was appointed to our Board of Directors in July 2014. Prior to his retirement in June 2010, Mr. Alleva worked with PricewaterhouseCoopers LLP, or PwC, for 39 years, 28 of which as a partner with the firm. Mr. Alleva served clients primarily in the technology sector, including numerous pharmaceutical and biotechnology companies. Additionally, he served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader (Assurance) for PwC from 2006 until his retirement. Mr. Alleva is a Certified Public Accountant (inactive). Mr. Alleva received a Bachelor of Science degree in accounting from Ithaca College (magna cum laude) and attended Columbia University’s Executive MBA Program. Mr. Alleva also serves as a director for public companies Tesaro Inc. and Bright Horizons Family Solutions, and previously served on the board of GlobalLogic Inc.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Elaine V. Jones, Ph.D.
Executive Director, Venture Capital-Worldwide Business Development, Pfizer Inc.

Mirna-Michael Powell
Dr. Elaine V. Jones joined Mirna’s board of directors in October 2012. Since December 2008, Dr. Jones has served as Executive Director, Venture Capital Investments of Pfizer Venture Investments, the venture capital arm of Pfizer, Inc. Dr. Jones is currently a director of Aquinox Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, where she also serves as the chair of the audit committee. She is also a director at Flexion Therapeutics, a pharmaceutical company, Autifony Therapeutics Ltd., a biotechnology company, and Mission Therapeutics Ltd., a biopharmaceutical company. Dr. Jones has also served as a General Partner with the venture fund, Euclid SR Partners, one of the venture funds of GlaxoSmithKline, plc. Dr. Jones received her Ph.D. in microbiology from the University of Pittsburgh.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Paul Lammers, M.D., M.Sc.
President & Chief Executive Officer

Mirna-Michael Powell
Dr. Paul Lammers has served as a member of Mirna’s board of directors and as President and Chief Executive Officer since November 2009. Previously, Dr. Lammers was the President of Repros Therapeutics Inc., a biopharmaceutical company. Dr. Lammers has also served as the Chief Medical Officer for EMD Serono, Inc., a biopharmaceutical division of Merck KGaA, Senior Vice President of clinical and regulatory affairs at Zonagen, Inc., which later became Repros Therapeutics, and Organon International, a pharmaceutical company, spending eight years in the commercial and clinical operations in Europe and the United States. Dr. Lammers received an M.Sc. and M.D. from the Catholic University (Radboud University) in Nijmegen, The Netherlands.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Ed Mathers
Partner, New Enterprise Associates (NEA)

Mirna-Michael Powell
Mr. Ed Mathers has served as a Partner at NEA, a private venture capital firm focusing on technology and healthcare investments since August 2008. Mr. Mathers became a member of Mirna’s board of directors in October 2012. He also serves on the board of directors of Envisia Therapeutics, Inc., a biopharmaceutical company; Liquidia Technologies, a biotechnology company; Ra Pharmaceuticals, a biotechnology company; and Lumos Pharma, a biotechnology company. Previously Mr. Mathers served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Previously, Mr. Mathers spent 15 years at Glaxo Wellcome, Inc., where he held various sales and marketing positions.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Clay B. Siegall, Ph.D.
President & Chief Executive Officer, Seattle Genetics

Mirna-Michael Powell
Dr. Clay B. Siegall joined the Mirna board of directors in January 2013. Dr. Siegall founded Seattle Genetics, Inc., a biotechnology company, in 1997, where he has served as the company’s Chief Executive Officer since November 2002, as President since June 2000 and Chairman of the board of directors since March 2004. Previously, Dr. Siegall also served as the Chief Scientific Officer of Seattle Genetics. He currently serves on the board of directors of Alder BioPharmaceuticals, Inc., a biopharmaceutical company, and Ultragenyx Pharmaceutical. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute, most recently as a Principal Scientist, and was a Staff Fellow/Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. He received a Ph.D. in genetics from George Washington University.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Matthew Winkler, Ph.D.
Founder and Chairman, Asuragen

Mirna-Michael Powell
Dr. Matt Winkler has served as a member of Mirna’s board of directors since December 2007. Since January 2013, Dr. Winkler has been chairman of the board of directors and Chief Scientific Officer of Asuragen, Inc., a molecular 

Scientific Advisors
 

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Corey Goodman, Ph.D. (Chairman)

Dr. Corey Goodman is a Managing Partner of venBio, a private equity firm specializing in life sciences and an Adjunct Professor at UC Berkeley. Dr. Goodman serves as Chairman of the board of directors of Second Genome, Oligasis, Solstice Biologics, Heart Metabolics, and Alexo Therapeutics and is a member of the board of directors of Checkmate Pharmaceuticals. Previously, Dr. Goodman co-founded each of Alexo, Labrys Biologics, Second Genome, Solstice, Exelixis, and Renovis, and served as CEO of Renovis. Dr. Goodman was the President of the Pfizer, Biotherapeutics and Bioinnovation Center. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. Dr. Goodman is Chair of the California Council on Science and Technology, and previously served as the Chair of the National Research Council’s Board on Life Sciences. Goodman previously served as a member of the board of directors of Mirna Therapeutics.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">David H. Johnson, M.D., M.A.C.P., F.A.S.C.O.

Mirna-Michael Powell
Dr. David H. Johnson is the Chairman of the Department of Internal Medicine at the University of Texas Southwestern Medical School in Dallas, Texas, and the Donald W. Seldin Distinguished Chair in Internal Medicine. Dr. Johnson served on the board of directors of the American Society of Clinical Oncology (ASCO), the American Board of Internal Medicine, the National Comprehensive Cancer Network (NCCN). Dr. Johnson also served on the Oncology Drug Advisory Committee (ODAC) at the Food and Drug Administration (FDA). Dr. Johnson is a recognized specialist in the area of non-small cell lung cancer.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Art Krieg, M.D.

Mirna-Michael Powell
Dr. Art Krieg serves as Founder and CEO at Checkmate Pharmaceuticals, and has worked in the oligonucleotide field since the 1980s. He co-founded Coley Pharmaceutical Group and served as the Chief Scientific Officer of Pfizer’s Oligonucleotide Therapeutics Unit. Dr. Krieg subsequently co-founded RaNA Therapeutics, and served as CSO at Sarepta Therapeutics. He co-founded the first antisense journal, Nucleic Acid Therapeutics, and the Oligonucleotide Therapeutic Society, for which he is currently President-elect.
 

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Frank J. Slack, Ph.D.

Mirna-Michael Powell
Dr. Frank J. Slack is the Director of the Institute for RNA Medicine in the Department of Pathology at BIDMC Cancer Center/Harvard Medical School. The Slack laboratory studies the roles of microRNAs and their targets in cancer, development and aging. He started work on microRNAs as a postdoctoral fellow in Dr. Gary Ruvkun’s laboratory at Harvard Medical School, where he co-discovered let-7, the first known human microRNA.
 

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Alan P. Venook, M.D.

Mirna-Michael Powell
Dr. Alan Venook is the Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California San Francisco, where he leads the Gastrointestinal Oncology clinical program. Dr. Venook was the founding Chair of the National Cancer Institute’s (NCI) Hepatobiliary Task Force. He served as Chair of the Gastrointestinal Committee of the Alliance for Clinical Trials in Oncology. An internationally recognized expert in colorectal and liver cancers, Dr. Venook is currently an Associate Editor of the Journal of Clinical Oncology. He was Chair of the Scientific Program for ASCO 2015.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Daniel D. Von Hoff, M.D.

Mirna-Michael Powell
Dr. Daniel D. Von Hoff is currently Physician in Chief, Distinguished Professor of Translational Research at TGen, and Chief Scientific Officer for US Oncology and for Scottsdale Healthcare’s Clinical Research Institute. He was appointed to President Bush’s National Cancer Advisory Board. Dr. Von Hoff is also the past President of the American Association for Cancer Research (AACR), was on the AACR and the American Society of Clinical Oncology's Board of Directors, and is a fellow of the American College of Physicians.

http://www.mirnarx.com/about/p7apm/img/p7apm_east_black.gif); background-position: 0px 9px; background-repeat: no-repeat;" rel="nofollow">Steve Weitman, M.D., Ph.D.

Mirna-Michael Powell
Dr. Steve Weitman is a Professor at the Institute for Drug 


 
Volume:
Day Range:
Last Trade Time:
Delayed by 15 minutes
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Detailed Quote
MIRN Latest News
  • No Recent News Available for this company!
More MIRN News
New Post